Annals of Oncology

(ISSN: 0923-7534, 1569-8041)

Subscribe Submit

Articles Available on Medscape

 
 

Annals of Oncology's Latest Table of Contents

2017 -

  • Efficacy and Safety of Nilotinib in Patients With KIT-Mutated Metastatic or Inoperable Melanoma: Final Results From the Global, Single-Arm, Phase II TEAM Trial. 
  • Statistical Controversies in Cancer Research: Using standardized effect size graphs to enhance interpretability of cancer-related clinical trials with patient reported outcomes. 
  • A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. 
  • Final overall survival analysis for the phase II RECORD-3 Study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. 
  • A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. 
  • Genomic characterisation of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy - results from the ACOSOG Z1041 (Alliance) trial. 
  • Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomised trial. 
  • A randomised phase III study of 72 hour infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). 
  • An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. 
  • Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. 
  • A Phase II Study of a Human Anti-PDGFRα Monoclonal Antibody (Olaratumab, IMC-3G3) in Previously Treated Patients with Unresectable and/or Metastatic Gastrointestinal Stromal Tumors. 
  • Reply to "Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study" by J. Furlanetto et al. 
  • Statistical controversies in clinical research Value of adverse events relatedness to study treatment: Analyses of data from randomized double-blind placebo-controlled clinical trials. 
  • Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. 
  • PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. 
  • Etoposide and Cisplatin vs Paclitaxel and Carboplatin With Concurrent Thoracic Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Multicenter Randomized Phase III Trial. 
  • Reply to the letter to the editor 'Sorafenib plus Hepatic Arterial Infusion Chemotherapy with Cisplatin vs. Sorafenib for Advanced Hepatocellular Carcinoma: Randomized Phase II Trial' by Fornaro et al. 
  • BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. 
 
 
Member of Medscape Publishers’ Circle®

About the Publication: Annals of Oncology, the journal of the European Society of Medical Oncology, is a multidisciplinary journal that publishes articles addressing medical oncology, surgery, radiotherapy, paediatric oncology, basic research and the comprehensive management of patients with malignant diseases.

Member of Medscape Publishers’ Circle®